Amyloidosis
1995; Lippincott Williams & Wilkins; Volume: 91; Issue: 4 Linguagem: Finlandês
10.1161/01.cir.91.4.1269
ISSN1524-4539
Autores Tópico(s)Dermatological and Skeletal Disorders
ResumoHomeCirculationVol. 91, No. 4Amyloidosis Free AccessResearch ArticleDownload EPUBAboutView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticleDownload EPUBAmyloidosis Robert A. Kyle Robert A. KyleRobert A. Kyle From the Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, and Mayo Medical School, Rochester, Minn. Originally published15 Feb 1995https://doi.org/10.1161/01.CIR.91.4.1269Circulation. 1995;91:1269–1271Amyloid appears homogeneous and amorphous under the light microscope but in reality consists of rigid, linear, nonbranching, aggregated fibrils 7.5 to 10 nm wide and of indefinite length. Each fibril consists of two to five filaments and is arranged in an antiparallel or cross–β-pleated sheet configuration, which is responsible for the unique staining and optical features. Congo red produces an apple-green birefringence with a polarized light source and is the most specific stain. Methyl violet, crystal violet, or thioflavin T also produce typical color changes. Electron microscopy reveals the fibrillar pattern. The amyloid fibrils deposit extracellularly and generally resist proteolytic digestion. These deposits lead to loss of normal tissue elements and disorganization of tissue architecture. In the United States, almost 85% of patients with systemic amyloidosis have the primary type (AL) in which the fibrils consist of monoclonal κ or λ light chains.1 Nephrotic syndrome or renal failure, congestive heart failure, carpal tunnel syndrome, sensorimotor peripheral neuropathy, and orthostatic hypotension are the most common presenting features. Weakness, fatigue, weight loss, edema, paresthesias, light-headedness or syncope, dyspnea, purpura or bleeding, or change in the voice are the most common symptoms. Hepatomegaly occurs in 25% of patients, whereas splenomegaly is present in less than 5% and macroglossia in only 10%. Anemia is infrequent unless multiple myeloma, renal insufficiency, or gastrointestinal bleeding occurs. Thrombocytosis is a diagnostic clue and occurs in 10%. Reduced renal function is present at diagnosis in 50% of patients. The serum protein electrophoretic pattern has a spike in almost one half of patients and hypogammaglobulinemia in one fifth of patients. A monoclonal protein (M protein) is found in the serum or urine in 90%. λ Light chains are twice as frequent as κ, whereas the reverse is true in multiple myeloma. Plasmacytosis is present in the bone marrow in more than one half of patients. An M protein in the serum or urine or monoclonal plasma cells in the bone marrow are found in 98% of patients with AL amyloidosis. Biopsy of abdominal fat or bone marrow is positive in 90% of patients. Congestive heart failure occurs in approximately one fourth of patients with AL. Electrocardiography often shows either low voltage in the limb leads or loss of anterior forces consistent with anterioseptal infarction, but there is no evidence of myocardial infarction at autopsy.2 Atrial fibrillation or heart block are common features. Echocardiography is abnormal in two thirds of patients at diagnosis. The major echocardiographic features are increased thickness of the left and right ventricular walls, abnormal myocardial texture (granular sparkling), valvular thickening and regurgitation, atrial enlargement, and pericardial effusion. Early cardiac amyloidosis is characterized by abnormal relaxation, whereas advanced involvement is characterized by restrictive hemodynamics. Eventually, systolic ventricular function fails. Hypertrophic obstructive cardiomyopathy or constrictive pericarditis may be difficult to differentiate from AL. Death is attributed to cardiac involvement from congestive heart failure or arrhythmias in at least one half of AL patients. The fibrils in secondary amyloidosis (AA) consist of protein A, a nonimmunoglobulin. Rheumatoid arthritis including its variants and chronic inflammatory bowel disease (mainly Crohn's disease) are the most common causes in Western Europe and the United States. Tuberculosis and leprosy are major causes in third-world countries. Renal insufficiency or nephrotic syndrome is seen in 90%, while the heart and peripheral nerves are rarely involved.3Although familial amyloidosis has been recognized for over four decades, it has been recognized rarely except in the endemic areas of Porto, Portugal, northern Sweden, and Japan until the last decade. Most commonly, familial amyloidosis presents as a sensorimotor peripheral neuropathy involving the lower extremities. Autonomic dysfunction and disturbances of bladder and gastrointestinal functions are prominent. Symptoms begin in the second or third decade of life, but in some patients, late onset is evident and symptoms do not occur until the sixth or seventh decade. In our experience, the median age is 62 years, and in many, a family history was not obtained until after systemic amyloidosis was recognized.4 Even in endemic areas, almost one third of patients with this autosomal dominant disorder had asymptomatic parents at the time of diagnosis.5 Familial amyloidosis may involve the kidney, as in familial Mediterranean fever, which is characterized by recurrent episodes of fever and abdominal pain and results in nephrotic syndrome and renal insufficiency. In other families, hypertension and renal failure are the major features. Cardiac amyloidosis producing congestive heart failure was reported in a large Danish family over 30 years ago.6 Cardiomyopathy was described in 1987 in a large kindred from the Appalachian region of the United States.7 The amyloid fibrils in these patients consist of a mutant of transthyretin (prealbumin). In this issue of Circulation, Booth et al8 report an Italian family with a new variant of transthyretin (TTR) associated with hereditary amyloidosis with a cardiac presentation. Almost 50 mutations of the TTR gene have been reported.9It is important to recognize familial amyloidosis because liver transplantation is beneficial. Because the variant TTR is produced by the liver, orthotopic liver transplantation results in disappearance of the variant TTR. Improvement of neurological symptoms and reduction in amyloid deposits have been reported after liver transplantation.10 In a group of seven patients with familial amyloidosis, only normal TTR was found after surgery. During short-term follow-up, none of the patients had clinical progression of amyloidosis.11 In a worldwide collection of cases, 53 of 64 patients survived a liver transplant for familial amyloidosis. In most of the patients surviving more than a year, the neurological symptoms stabilized and autonomic nervous system symptoms improved.12 Ideally, liver transplantation should be performed before symptomatic cardiac amyloidosis occurs. If cardiac function is compromised, resulting in congestive heart failure, a cardiac transplant must be done before the liver transplant. The fibrils in senile cardiac amyloidosis consist of normal TTR. Cardiac amyloid was found in 9 of 40 autopsied patients aged 90 years or over. In four of them, amyloid deposits were extensive and produced chronic congestive heart failure.13 Johannson and Westermark14 studied 12 hearts in which 40% or more of the left ventricle was replaced by amyloid. Atrial fibrillation had been present in 9 patients, while 7 died of congestive heart failure. In a review of 237 autopsies on patients 90 years of age or more, senile cardiac amyloidosis was detected in 154 (65%).15 Extensive involvement of the atria, ventricles, or heart valves was found in one third of these patients. Amyloidosis was believed to be responsible for death in 22 of the 154 patients.Although senile cardiac amyloidosis is commonly recognized at autopsy in the elderly, it may be recognized before death.16 These patients presented with dyspnea, weakness, and fatigue from congestive heart failure or atrial fibrillation. The echocardiogram revealed low voltage and often a pseudoinfarction pattern. The echocardiogram was characterized by increased ventricular wall thickness in the absence of hypertension, thickening of the valves, regurgitation, and pericardial effusion. Endomyocardial biopsy revealed amyloid. The most common cause of amyloidosis in this clinical setting is primary amyloidosis. There are no distinguishing clinical or laboratory features that differentiate patients with senile cardiac amyloidosis from those with nonsecretory immunoglobulin-derived amyloidosis (AL). Two important findings raise the possibility of senile cardiac amyloidosis: (1) the absence of a monoclonal protein in the serum or urine and (2) patients with senile cardiac amyloidosis do not have extracardiac manifestations such as renal insufficiency, nephrotic syndrome, peripheral neuropathy, orthostatic hypotension, steatorrhea, macroglossia, or purpura. Familial amyloidosis must also be distinguished from AL or senile cardiac amyloidosis because hereditary amyloidosis may not present until the sixth or seventh decade, and a positive family history is often lacking. Differentiation of nonsecretory AL from familial and senile amyloidosis is critical because of the differences in survival and therapy. In our experience, the median survival of patients with AL presenting with congestive heart failure is 4 months, whereas it is 5 years for those with senile cardiac amyloidosis. Furthermore, patients with AL are treated with melphalan and prednisone or other alkylating agents,1718 whereas familial amyloidosis is treated with liver transplantation. No specific therapy exists for senile cardiac amyloidosis. The clinician usually suspects primary amyloidosis and searches for a monoclonal protein in the serum and urine. When no monoclonal protein is detected, it is often concluded that the patient has nonsecretory primary amyloidosis, which occurs in about 10% of patients with AL. Immunohistochemical staining of the biopsy with antisera to TTR, κ and λ light chains, and amyloid A is necessary for accurate classification in this setting.19 If the stain for TTR is positive, the patient has either familial or senile amyloidosis, and DNA must be examined for a TTR mutation. It is critical that the correct diagnosis be made because of the differences in management and in survival. The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. FootnotesCorrespondence to Dr R.A. Kyle, Mayo Clinic, 200 First St SW, Rochester, MN 55905. References 1 Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol.1995; 32:45-59. MedlineGoogle Scholar2 Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc.1984; 59:547-555. CrossrefMedlineGoogle Scholar3 Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine.1991; 70:246-256. CrossrefMedlineGoogle Scholar4 Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc.1991; 67:428-440. Google Scholar5 Coelho T, Sousa A, Lourenço E, Ramalheira J. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet.1994; 31:293-299. CrossrefMedlineGoogle Scholar6 Frederiksen T, Gøtzsche H, Harboe N, Kiær W, Mellemgaard K. Familial primary amyloidosis with severe amyloid heart disease. Am J Med.1962; 33:328-348. CrossrefMedlineGoogle Scholar7 Benson MD, Wallace MR, Tejada E, Baumann H, Page B. Hereditary amyloidosis: description of a new American kindred with late onset cardiomyopathy: Appalachian amyloid. Arthritis Rheum.1987; 30:195-200. CrossrefMedlineGoogle Scholar8 Booth DR, Tan SY, Hawkins PN, Pepys MB, Frustaci A. A novel variant of transthyretin, 59Thr→Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation.1995; 91:962-967. CrossrefMedlineGoogle Scholar9 Uemichi T, Liepnieks JJ, Altland K, Benson MD. Identification of a novel non-amyloidogenic transthyretin polymorphism (His 74) in the German population. Amyloid: Int J Exp Clin Invest.1994; 1:149-153. Google Scholar10 Holmgren C, Ericzon B-G, Groth C-G, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet.1993; 341:1113-1116. CrossrefMedlineGoogle Scholar11 Skinner M, Lewis WD, Jones LA, Kasirsky J, Kane K, Ju S-T, Jenkins R, Falk RH, Simms RW, Cohen AS. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med.1994; 120:133-134. CrossrefMedlineGoogle Scholar12 Steen L, Holmgren G, Suhr O, Wikström L, Groth C-G, Ericzon B-G. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid: Int J Exp Clin Invest.1994; 1:138-142. Google Scholar13 Waller BF, Roberts WC. Cardiovascular disease in the very elderly: analysis of 40 necropsy patients aged 90 years or over. Am J Cardiol.1983; 51:403-421. CrossrefMedlineGoogle Scholar14 Johannson B, Westermark P. Senile systemic amyloidosis: a clinicopathological study of twelve patients with massive amyloid infiltration. Int J Cardiol.1991; 32:83-92. CrossrefMedlineGoogle Scholar15 Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc.1988; 63:552-564. CrossrefMedlineGoogle Scholar16 Olson LJ, Gertz MA, Edwards WD, Li C-Y, Pellikka PA, Holmes DR Jr, Tajik AJ, Kyle RA. Senile cardiac amyloidosis with myocardial dysfunction: diagnosis by endomyocardial biopsy and immunohistochemistry. N Engl J Med.1987; 317:738-742. CrossrefMedlineGoogle Scholar17 Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med.1985; 79:708-716. CrossrefMedlineGoogle Scholar18 Kyle RA, Gertz MA, Garton JP, Greipp PR, Witzig TE, Lust JA. Primary systemic amyloidosis (AL): randomized trial of colchicine vs melphalan and prednisone vs melphalan, prednisone, and colchicine. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds. Amyloid and Amyloidosis, 1993. New York: Parthenon Publishing; 1994:648-650. Google Scholar19 Linke RP, Nathrath WBJ, Eulitz M. Classification of amyloid syndromes from tissue sections using antibodies against various amyloid fibril proteins: report of 142 cases. In: Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, Zucker-Franklin D, eds. Amyloidosis, 1986. New York: Plenum Publishers; 1986:599-605. Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Yu M, Ji L, Li S, Zhang Y, Sun X, Sun R, Chen X, Luo Y and Cui X (2022) Exosomal circ-CACNG2 promotes cardiomyocyte apoptosis in multiple myeloma via modulating miR-197-3p/caspase3 axis, Experimental Cell Research, 10.1016/j.yexcr.2022.113229, 417:2, (113229), Online publication date: 1-Aug-2022. Jamshidi P, Levi J, Suarez M, Rivera R, Mahoney N, Eberhart C, Rosenberg A and Rodriguez F (2021) Clinicopathologic and Proteomic Analysis of Amyloidomas Involving the Ocular Surface and Adnexa, American Journal of Clinical Pathology, 10.1093/ajcp/aqab161, 157:4, (620-627), Online publication date: 1-Apr-2022. Harb S, Asher C and Klein A (2021) Primary Restrictive, Infiltrative, and Storage Cardiomyopathies Diastology, 10.1016/B978-0-323-64067-1.00023-1, (290-307), . Gutiérrez-García G, Cibeira M, Rovira M, Fernández de Larrea C, Tovar N, Rodríguez-Lobato L, Rosiñol L, Marín P, Solano-Vega J, Suárez-Lledó M, Bataller A, Solano M, de Llobet N, Domenech A, Borràs N, Lozano M, Cid J, Martínez C, Urbano-Ispizua Á, Esteve J, Carreras E, Fernández-Avilés F and Bladé J (2019) Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis, Bone Marrow Transplantation, 10.1038/s41409-019-0447-y, 54:8, (1295-1303), Online publication date: 1-Aug-2019. Boldueva S, Petrova V, Khavinson V, Samohvalova M and Petrova A (2020) Problems in the Diagnostics and Treatment of Transtiretinum Amyloidosis with Heart Disease in the Elderly: Clinical Experience, Advances in Gerontology, 10.1134/S2079057019040039, 9:4, (466-471), Online publication date: 1-Oct-2019. Zloto O, Rosner M and Vishnevskia-Dai V (2019) Yellow subconjunctival deposits, BMJ Case Reports, 10.1136/bcr-2019-230370, 12:7, (e230370), Online publication date: 1-Jul-2019. Baroni M, Nava S, Quattrocchi G, Milazzo A, Giannattasio C, Roghi A and Pedrotti P (2017) Role of cardiovascular magnetic resonance in suspected cardiac amyloidosis: late gadolinium enhancement pattern as mortality predictor, Netherlands Heart Journal, 10.1007/s12471-017-1046-4, 26:1, (34-40), Online publication date: 1-Jan-2018. Batra K, Dessouky R, Butt Y, Wadhwa V, Torrealba J and Glazer C (2018) Series of rare lung diseases mimicking imaging patterns of common diffuse parenchymal lung diseases, Lung India, 10.4103/lungindia.lungindia_291_17, 35:3, (231), . Blandford A, Yordi S, Kapoor S, Yeaney G, Cotta C, Valent J, Perry J and Singh A (2018) Ocular Adnexal Amyloidosis: A Mass Spectrometric Analysis, American Journal of Ophthalmology, 10.1016/j.ajo.2018.05.032, 193, (28-32), Online publication date: 1-Sep-2018. Colan S (2017) Restrictive Cardiomyopathy Associated With Skeletal Myopathies Cardioskeletal Myopathies in Children and Young Adults, 10.1016/B978-0-12-800040-3.00007-8, (137-152), . Raina S, Lensing S, Nairooz R, Pothineni N, Hakeem A, Bhatti S and Pandey T (2016) Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2016.01.036, 9:11, (1267-1277), Online publication date: 1-Nov-2016. K K P, K M, R K, P C and H V (2015) CARDIAC AMYLOIDOSIS IN A PATIENT WITH MULTIPLE MYELOMA, Journal of Evolution of Medical and Dental Sciences, 10.14260/jemds/2015/2026, 4:81, (14248-14252), Online publication date: 8-Oct-2015. LaSorda M and Marcotte G (2015) Angioedema of the tongue with an unfamiliar final diagnosis, Annals of Allergy, Asthma & Immunology, 10.1016/j.anai.2015.02.015, 114:4, (269-272), Online publication date: 1-Apr-2015. Aggarwal N, Peterson T, Young P, Araoz P, Glockner J, Mankad S and Williamson E (2014) Unveiling nonischemic cardiomyopathies with cardiac magnetic resonance, Expert Review of Cardiovascular Therapy, 10.1586/14779072.2014.876900, 12:2, (217-239), Online publication date: 1-Feb-2014. Hughes S (2013) Cardiomyopathies Cardiac Pathology, 10.1007/978-1-4471-2407-8_11, (183-200), . Suradi H, Bitar A, Benson M and Das M (2013) Predictors of survival among 60 patients with tissue proven primary cardiac amyloidosis, Open Journal of Clinical Diagnostics, 10.4236/ojcd.2013.32006, 03:02, (23-29), . Renapurkar R and Kanne J (2013) Metabolic and storage lung diseases: spectrum of imaging appearances, Insights into Imaging, 10.1007/s13244-013-0289-x, 4:6, (773-785), Online publication date: 1-Dec-2013. Isabel C, Georgin-Lavialle S, Aouba A, Delarue R, Nochy D, Karras A, Azarine A, Hermine O, Ranque B, Hagège A and Pouchot J (2013) Amylose cardiaque : à propos d'une série de 14 patients, description et facteurs pronostiques, La Revue de Médecine Interne, 10.1016/j.revmed.2013.05.003, 34:11, (671-678), Online publication date: 1-Nov-2013. BARRA S, PROVIDÊNCIA R, PAIVA L, NASCIMENTO J and MARQUES A (2012) A Review on Advanced Atrioventricular Block in Young or Middle-Aged Adults, Pacing and Clinical Electrophysiology, 10.1111/j.1540-8159.2012.03489.x, 35:11, (1395-1405), Online publication date: 1-Nov-2012. Arguelles E, Rodriguez Y, Baltodano P and Carrillo R (2011) Systemic amyloidosis presenting as constrictive pericarditis in a young adult, International Journal of Cardiology, 10.1016/j.ijcard.2010.12.108, 153:1, (e7-e9), Online publication date: 1-Nov-2011. Bhat A, Selmi C, Naguwa S, Cheema G and Gershwin M (2009) Currents Concepts on the Immunopathology of Amyloidosis, Clinical Reviews in Allergy & Immunology, 10.1007/s12016-009-8163-9, 38:2-3, (97-106), Online publication date: 1-Apr-2010. Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F and Matucci-Cerinic M (2010) Systemic amyloidosis: a challenge for the rheumatologist, Nature Reviews Rheumatology, 10.1038/nrrheum.2010.84, 6:7, (417-429), Online publication date: 1-Jul-2010. QU Z, ZHENG X, WANG S, AO J, ZHOU F, CHEN M and LIU G (2010) Clinical and pathological features of renal amyloidosis: An analysis of 32 patients in a single Chinese centre, Nephrology, 10.1111/j.1440-1797.2009.01127.x, 15:1, (102-107), Online publication date: 1-Feb-2010. Petruzziello F, Zeppa P, Catalano L, Cozzolino I, Gargiulo G, Musto P, D'Auria F, Liso V, Rizzi R, Caruso N, Califano C, Piro E, Musso M, Bonanno V, Pia Falcone A, Tafuto S, Di Raimondo F, De Laurentiis M, Pane F, Palombini L and Rotoli B (2009) Amyloid in bone marrow smears of patients affected by multiple myeloma, Annals of Hematology, 10.1007/s00277-009-0857-9, 89:5, (469-474), Online publication date: 1-May-2010. Sedaghat D, Zakir R, Choe J, Klapholz M and Saric M (2009) Cardiac amyloidosis in a patient with multiple myeloma: A case report and review of literature, Journal of Clinical Ultrasound, 10.1002/jcu.20552, 37:3, (179-184), Online publication date: 1-Mar-2009. Uliasz A and Lebwohl M (2008) Cutaneous manifestations of cardiovascular diseases, Clinics in Dermatology, 10.1016/j.clindermatol.2007.10.014, 26:3, (243-254), Online publication date: 1-May-2008. ASHER C and KLEIN A (2008) Primary Restrictive, Infiltrative, and Storage Cardiomyopathies Diastology, 10.1016/B978-1-4160-3754-5.50027-5, (259-276), . Yagi S, Akaike M, Ozaki S, Moriya C, Takeuchi K, Hara T, Fujimura M, Sumitomo Y, Iwase T, Ikeda Y, Aihara K, Kimura T, Nishiuchi T, Abe M and Matsumoto T (2007) Improvement of Cardiac Diastolic Function and Prognosis After Autologous Peripheral Blood Stem Cell Transplantation in AL Cardiac Amyloidosis, Internal Medicine, 10.2169/internalmedicine.46.0142, 46:20, (1705-1710), . NAQVI T (2007) Restrictive Cardiomyopathy: Diagnosis and Prognostic Implications The Practice of Clinical Echocardiography, 10.1016/B978-1-4160-3640-1.50033-2, (679-709), . Garibaldi B and Zaas D (2007) An Unusual Case of Cardiac Amyloidosis, Journal of General Internal Medicine, 10.1007/s11606-007-0207-3, 22:7, (1047-1052), Online publication date: 5-Jun-2007. Hughes S (2007) The role of the pathologist in the diagnosis of cardiomyopathy: a personal view Progress in Pathology, 10.1017/CBO9780511545955.006, (101-134) Niedeggen A, Breithardt O and Franke A (2005) Detection of early systolic dysfunction with strain rate imaging in a patient with light chain cardiomyopathyNachweis einer fr�hen systolischen Funktionsst�rung mittels strain rate imaging bei einem Patienten mit kardialer Amyloidose, Zeitschrift f�r Kardiologie, 10.1007/s00392-005-0175-8, 94:2, (133-136), Online publication date: 1-Feb-2005. Parikh S and Lemos J (2005) Current therapeutic strategies in cardiac amyloidosis, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-005-0029-8, 7:6, (443-448), Online publication date: 1-Nov-2005. Soni A and LeLorier P (2005) Sudden death in nondilated cardiomyopathies: Pathophysiology and prevention, Current Heart Failure Reports, 10.1007/s11897-005-0019-x, 2:3, (118-123), Online publication date: 1-Sep-2005. Larkin J, Frank B, Gaspard R, Duka I, Gavras H and Quackenbush J (2004) Cardiac transcriptional response to acute and chronic angiotensin II treatments, Physiological Genomics, 10.1152/physiolgenomics.00057.2004, 18:2, (152-166), Online publication date: 8-Jul-2004. Andrews T, Colon-Otero G, Calamia K, Menke D, Boylan K and Kyle R (2002) Utility of Subcutaneous Fat Aspiration for Diagnosing Amyloidosis in Patients With Isolated Peripheral Neuropathy, Mayo Clinic Proceedings, 10.4065/77.12.1287, 77:12, (1287-1290), Online publication date: 1-Dec-2002. Kotha A and Weiss M (2002) Cardiac Amyloidosis: A Case Report and Therapeutic Implications, Heart Disease, 10.1097/00132580-200203000-00005, (86-90), Online publication date: 1-Mar-2002. Pelo E, Prato L, Ciaccheri M, Castelli G, Gori F, Pizzi A, Torricelli F and Marconi G (2009) Familial amyloid polyneuropathy with genetic anticipation associated to a gly47glu transthyretin variant in an Italian kindred, Amyloid, 10.3109/13506120209072443, 9:1, (35-41), Online publication date: 1-Jan-2002. Ogawa H, Mizuno Y, Ohkawara S, Tsujita K, Ando Y, Yoshinaga M and Yasue H (2016) Cardiac Amyloidosis Presenting as Microvascular Angina, Angiology, 10.1177/000331970105200407, 52:4, (273-278), Online publication date: 1-Apr-2001. Cabot R, Scully R, Mark E, McNeely W, Ebeling S, Phillips L, Ellender S, DiSalvo T, King M and Smith R (2000) Case 3-2000, New England Journal of Medicine, 10.1056/NEJM200001273420408, 342:4, (264-273), Online publication date: 27-Jan-2000. Romero-Menor C, López-Gómez D, Iráculis E, Sabaté X, Esplugas E and García F (1999) Bloqueo auriculoventricular completo y taquicardia ventricular polimorfa como manifestación inicial de amiloidosis secundaria, Revista Española de Cardiología, 10.1016/S0300-8932(99)75049-9, 52:12, (1.157-1.158), Online publication date: 1-Jan-1999. Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C and Gavelli G (1998) Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy, American Heart Journal, 10.1016/S0002-8703(98)70127-9, 136:5, (824-830), Online publication date: 1-Nov-1998. Fernández-Yáñez J, Palomo J, Castellano N, García J, de la Villa B and Luis Delcán J (1997) Repercusión cardíaca de la amiloidosis y de la hemocromatosis, Revista Española de Cardiología, 10.1016/S0300-8932(97)74682-7, 50:11, (790-801), Online publication date: 1-Jan-1997. February 15, 1995Vol 91, Issue 4 Advertisement Article InformationMetrics Copyright © 1995 by American Heart Associationhttps://doi.org/10.1161/01.CIR.91.4.1269 Manuscript receivedDecember 28, 1994Manuscript acceptedDecember 29, 1994Originally publishedFebruary 15, 1995 KeywordsbiopsyproteinsEditorialsheart failure Advertisement
Referência(s)